DVAX
Dynavax Technologies Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$15.50
+0.00%Year over year
Reported trailing growth
- Revenue
- +26.7%
- EBITDA
- —
- EBIT
- +203.2%
- EPS
- —
- Free cash flow
- +255.3%
- Operating cash flow
- +232.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.2%
- EBITDA
- -21.9%
- EBIT
- +88.9%
- Net income
- -29.1%
- EPS
- -30.3%
- Free cash flow
- -43.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025